139. Kesselheim AS and Mello MM. Confidentiality laws and secrecy in medical research: improving access to drug safety data. Health Affairs. 2007; 26(2):483-491.
140. Kesselheim AS and Avorn J. The role of litigation in drug safety. Journal of the American Medical Association. 2007; 297(3):308-311.
141. Kesselheim AS and Studdert DM. Author Reply: Characteristics of physicians who frequently act as expert witnesses in neurological birth injury litigation. Obstetrics & Gynecology. 2006; 108(6):1552-1553.
142. Kesselheim AS, Mello MM. Medical process patents – monopolizing the delivery of health care. New England Journal of Medicine. 2006; 355(19):2036-2041.
143. Kesselheim AS, Fischer MA, Avorn J. Extensions of intellectual property rights and delayed adoption of generic drugs: effects on Medicaid spending. Health Affairs. 2006; 25(6):1637-1647.
150. Friedberg MA and Kesselheim AS. Establishing a medico-legal and health policy education curriculum for medical residents. Journal of General Internal Medicine. 2006; 21 suppl. 4:172.
151. Kesselheim AS and Avorn J. Biotechnology products and university-based science. Journal of the American Medical Association. 2005; 293(23):2863.
152. Kesselheim AS and Brennan TA. Overbilling vs. downcoding — the battle between physicians and insurers. New England Journal of Medicine. 2005; 352(9):855-857.
153. Kesselheim AS and Avorn J. University-based science and biotechnology research: defining the boundaries of intellectual property. Journal of the American Medical Association. 2005; 293(7):850-854.
159. Kissick WL and Kesselheim AS. Presidential disability: the panel of physicians. Transactions & Studies of the College of Physicians of Philadelphia. 2001; 23:113-119.
160. Kesselheim AS. Ensuring quality end-of-life cancer care: an analysis of the current state of patient and family information about end-of-life care issues, its deficiencies, and recommendations for the future. Gelband H & Foley KM, eds. Excellent end-of-life care for cancer patients: a policy agenda for action and research. 2001; 132-152.
161. Kesselheim AS. What’s the appeal? Trying to control managed care medical necessity decisionmaking through a system of external appeals. University of Pennsylvania Law Review. 2001; 149(3):873-920.